ALSO READSuven gets three process patents for neuro-degenerative drug Buy ACC, Suven Life Sciences, says Prabhudas Lilladher Jubilant Life Sciences Q1 net down 12% to Rs 143 crore Strand Life Sciences launches special test for early cancer detection Jubilant Life shares jump 7% as Q4 net profits zooms 14-fold
In a BSE filing today, Suven Life said it has been granted "one product patent from New Zealand corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases".
The patents are valid till 2034, the company added.
Suven Life CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally."
Suven Life Sciences stock was trading 6.08 per cent up at Rs 192 on the BSE in the morning trade.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)